SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma.

Dalgleish, AG; McLean, E; Patel, N; Rahman, N (2020) Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma. Respir Med Case Rep, 29. p. 100971. ISSN 2213-0071 https://doi.org/10.1016/j.rmcr.2019.100971
SGUL Authors: Dalgleish, Angus George

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (536kB) | Preview

Abstract

A 64 year old male heating engineer was investigated for a persistent cough and found to have epithelioid mesothelioma with pleural effusion, lung nodules and increased thoracic lymph nodes. He declined standard of care treatment following his own research and he was enrolled in a named patient programme of IMM-101. He was advised to correct his low vitamin D3 level and to start using anti-inflammatories such as aspirin, bromelain and low dose Naltrexone. At review one year later a CT scan showed no change and he continued on the regimen. Four years after the diagnosis a CT scan showed that there was a modest but definite progression of the left malignant pleural thickening, and a new right-sided effusion, enlargement of several intrathoracic nodes which had been noted on the early scans. The chest wall lump eventually broke down and required local radiotherapy. He then developed abdominal pain and found to have peritoneal disease. Last year he obtained the cannabinoids CBD and THC which slowed down the disease and a CT scan after he had been on this for six months, showed that his disease was fairly stable with marginal progression.

Item Type: Article
Additional Information: Crown Copyright © 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
Keywords: Anti-inflammatory, IMM-101-015, Immunotherapy, Mesothelioma
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Respir Med Case Rep
ISSN: 2213-0071
Language: eng
Dates:
DateEvent
21 November 2019Published Online
20 November 2019Accepted
2020Published
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
PubMed ID: 31788420
Go to PubMed abstract
URI: http://openaccess.sgul.ac.uk/id/eprint/111461
Publisher's version: https://doi.org/10.1016/j.rmcr.2019.100971

Actions (login required)

Edit Item Edit Item